DLA Piper advises RIS Rx in securing growth investment from Summit Partners

DLA Piper advised RIS Rx, a healthcare technology company, in securing a significant growth investment from Summit Partners, a leading growth-focused investment firm.

RIS Rx provides solutions to reduce revenue leakage in pharmaceutical gross-to-net spread. This transaction will support RIS Rx’s continued innovation and growth, in addition to the company’s commitment to improving patient access to treatment. RIS Rx will use the investment to accelerate product development, grow its team, and enhance client services.

"We are thrilled to have supported RIS Rx in securing this significant investment. This partnership will empower RIS Rx to enhance and expand its innovative solutions, ultimately improving patient access to drug affordability programs and financial assistance,” said Adam Spector, the DLA Piper partner who led the deal team.

The DLA Piper team was led by partner Adam Spector (Chicago) and included partners Scott Kapp and Jason Veit (both in Chicago), Jordan Bailowitz (Baltimore), and Kristi Kung (Washington, DC), and associates Christine Korper, Landon Wilneff, and Kyle Stearns (all in Chicago) and Dan Kagan (New York).

With more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 15 consecutive years, according to Mergermarket, and ranked as number one in VC, PE and M&A in combined global deal volume according to PitchBook.